Crescendo Biologics Ltd. announced that Takeda Pharmaceutical Company Limited (Takeda) is planning to evaluate the application of recently licensed Humabodies from Crescendo for the development of novel CAR-T therapeutics. This research will investigate the unique properties of the Humabody® VHs for tumour targeting of CAR-Ts. Unlike single-chain variable fragments (scFvs), Humabody® VHs do not require a light chain for high specificity and affinity, and can be easily configured for multi-specific target binding. Takeda’s decision to license these Humabodies provides an opportunity to evaluate a large number of different VHs directed to the same target, in order to identify a format that delivers both enhanced safety and functionality.